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Background: Smoking in pregnancy is a public health problem. Self-help smoking cessation support can help
pregnant women to stop smoking, but the effects of delivering this kind of support via SMS text message are not
known. A previous randomised controlled trial (RCT) demonstrated the feasibility and acceptability of providing
such support to pregnant smokers using an automated, tailored text message intervention called MiQuit. This larger
RCT will estimate key parameters for and will test the feasibility of delivering a major trial run within the United
Kingdom National Health Service settings aimed at providing definitive evidence on the utility of MiQuit for helping
pregnant smokers to stop.
Methods/Design: This will be a multi-centre, parallel group RCT. Participants are being identified in 16 English
antenatal care settings and must be >16 years old, pregnant, <25 weeks gestation, smoke >1 daily cigarette, have
smoked >5 daily cigarettes before pregnancy, and able to understand texts in English. After consenting and the
collection of baseline data, participants are randomised to control or intervention groups in a 1:1 ratio; randomisation is
stratified by trial site and gestation and employs computer-generated pseudo-random code using random permuted
blocks of randomly varying size, and held on a secure server. All participants receive a National Health Service (NHS) leaflet
aimed at helping them to stop smoking. Intervention group women also receive the 12-week MiQuit programme of
tailored, supportive, interactive text message, self-help cessation support. Women are followed up by telephone 4 weeks
after randomisation and at 36 weeks gestation. The study aims to recruit 400 women, and with this sample we will be
able to estimate trial centres’ recruitment rates to within +/−1% (margin of error = half width of 95% confidence
interval); individual trial groups’ ascertainment of rates for smoking outcomes between 4 weeks after randomisation
until approximately 36 weeks gestation to within +/−4%, and across both groups, the combined cessation rate at
36 weeks +/−3%.
Discussion: Pilot trial completion will provide data to facilitate planning for a definitive trial investigating whether
MiQuit works for smoking cessation in pregnancy.
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Epidemiological evidence indicates that smoking during
pregnancy increases the risk of many pregnancy-related
complications including low birth weight, preterm birth,
spontaneous abortions, stillbirth, ectopic pregnancy and
neonatal death and is associated with many adverse
postnatal problems including impaired lung function
and Sudden Infant Death Syndrome [1]. Taking into ac-
count that between one in four [2] and one in eight [3]
women are estimated to smoke during pregnancy, the
consequences of prenatal smoking come at a great finan-
cial cost to the health service.
A review of smoking cessation interventions for preg-
nant smokers indicates that such interventions can be
effective at increasing cessation during pregnancy, al-
though the increase is fairly modest [4]. Although smok-
ing cessation support is offered to pregnant smokers
through the NHS Stop Smoking Services in England, up-
take rates are fairly low [5,6]. While it is important to
explore ways of increasing the uptake of face-to-face
specialist support among this population, it is equally
important to explore the potential of alternative forms
of support.
One such alternative is self-help. A recent review of
the literature indicates that self-help interventions for
pregnant smokers almost double the chances of quitting
compared with usual care [7]. Furthermore, self-help has
been identified as being of high interest to pregnant
smokers interested in quitting smoking [8]. It is also
generally of low cost and, potentially, has wide reach.
One promising mode of delivery for self-help support is
through mobile phone text messages. A recent large trial
of a text message smoking cessation intervention for
non-pregnant smokers found it doubled cessation rates
compared with a no-intervention control group [9]. Re-
garding its potential for pregnant smokers, mobile
phone ownership is high across the social class spectrum
in the UK, and text messaging is particularly popular
among those under 45 years of age [10].
A pilot trial of a tailored self-help intervention devel-
oped for pregnant smokers in Cambridge (called MiQuit)
found that delivering support by text message to pregnant
smokers was feasible and also acceptable for recipients
[11]. Furthermore, the MiQuit intervention increased the
likelihood of women setting a quit date and increased
women’s harm beliefs (related to smoking) and confidence
in their ability and determination to quit. Although this
trial was small (n = 207), it provided an estimate for
MiQuit’s efficacy, albeit with wide 95% confidence intervals,
which suggests that this intervention could be a valuable
addition to standard NHS support for smoking cessation in
pregnancy. At 12 weeks after randomisation, 12.5% of
women who used MiQuit reported not having smoked in
the previous 7 days, which was validated using salivarycotinine assessment, compared with only 7.8% in the con-
trol group; if MiQuit could have such an impact in routine
NHS care, its low cost would make it highly cost-effective.
Before MiQuit could be used in routine care, a defini-
tive randomised controlled trial would need to prove its
effectiveness, so obtaining further evidence concerning
its efficacy is appropriate. However, such a trial would
need to be very large and expensive and, currently, there
is insufficient information to justify conducting this. For
example, it is not known if cessation encouraged by
MiQuit, in the pilot trial, which was measured, at
12 weeks after randomisation (around mid-pregnancy),
persists beyond this point. However, sustained cessation
throughout pregnancy would be required before one
could expect this potentially-useful intervention to have
a meaningful impact on fetal health. Also, there is only
very limited information with which one could plan a
definitive trial such that this made efficient use of re-
search resources; for example, likely recruitment and
follow-up rates need determining. Consequently, we
propose a pilot trial, which will investigate whether or
not it is possible to evaluate MiQuit in a multi-centre
RCT located within the NHS research infrastructure,
taking full advantage of appropriate NHS research net-
work resources. This study will provide estimates for the
following parameters, which will be of crucial import-
ance when deciding upon resources required for a de-
finitive trial: the range of likely recruitment rates in
different centres; quit rates amongst trial participants;
feasibility of assessing smoking status of trial participants
in later pregnancy; ascertainment rates obtained; and the
likely effect of MiQuit when women are offered this in
NHS settings. Findings from the pilot trial will permit
estimation of the likely impact of MiQuit being intro-
duced into routine clinical practice.
Aims and objectives
The aim of this trial is to estimate the likely impact of the
MiQuit text message-based smoking cessation interven-
tion for pregnant smokers and to establish robust esti-
mates for key parameters, which would be required in
order to design a definitive trial of this intervention.
Primary objective
The primary objective of this study is to estimate the key
parameters required in order to design a definitive trial
testing the efficacy of MiQuit, including the following:
1. Recruitment rates within pregnant smokers
attending hospital recruitment centres
2. For individual trial groups, rates of ascertainment of
validated smoking cessation between 4 weeks after
randomisation until late pregnancy (approximately
36 weeks)
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Secondary objectives
The secondary objectives are as follows:
1. To estimate and model the likely effectiveness and
cost effectiveness of MiQuit compared with usual
care including a generic smoking cessation
information leaflet.
2. To document participants’ use of MiQuit interactive
features and of NHS cessation support.
3. To assess the effect of MiQuit on social cognitive
determinants of quitting smoking.
4. To explore participant views and experiences of
using MiQuit.
5. To explore research staff views and experiences of
the MiQuit pilot trial.
Methods/Design
Trial design
This study is a multicentre, two-arm, parallel group, sin-
gle blind, randomised controlled trial testing the MiQuit
text message smoking cessation support system in preg-
nant women.
Study setting
Participants will be recruited from hospital antenatal
clinics in England.
Eligibility criteria
To be eligible for the trial participants must be i) preg-
nant and less than 25 weeks gestation, ii) have smoked
at least 5 cigarettes per day pre-pregnancy and have con-
tinued to smoke at least 1 cigarette on a typical day dur-
ing pregnancy, iii) aged 16 or over, iv) agree to accept
information to assist cessation, v) have their own or have
primary use of a mobile phone, vi) be familiar with send-
ing and receiving text messages, vii) be able to under-
stand written English (text messages are in English only)
and consent issues explained in English, and viii) be able
to give informed consent.
They should not already be enrolled in another text
service to assist smoking cessation.
Intervention
MiQuit is an automated responsive text message support
programme lasting 12 weeks, which provides tailored
smoking cessation support and advice to the partici-
pant’s mobile phone. The MiQuit system provides advice
and support content that is tailored to 12 characteristics
of the individual at baseline and is tailored to changes in
smoking status collected at two time points during the
12-week programme. In addition, participants can textin a quit date and receive additional support tailored
around this date. Participants can also increase or de-
crease the frequency of support they receive at any time
by texting the keywords MORE or LESS. The support
includes motivational messages, advice about preparing
for a quit attempt, how to manage cravings and with-
drawal, dealing with trigger situations, information about
how smoking affects babies and general encouragement.
Participants will receive between 70 and 145 texts over
12 weeks (0.8 to 1.7 texts per day), dependent upon how
they use the system. They also will have the ability to re-
quest instant support text messages on demand or dis-
traction messages by texting one of three keywords to
the MiQuit system. Any text message replies to MiQuit
made by participants will be charged at the usual net-
work rate or included in their text allowance, but texts
they received from MiQuit are free. All likely costs to
participants will be made clear in the participant infor-
mation sheet (PIS).
In addition to the MiQuit text message intervention,
intervention group participants will receive a standard
NHS leaflet giving some information and advice on stop-
ping smoking and usual NHS antenatal care.
Control
Control group participants will receive the same NHS
leaflet giving some information and advice on stopping
smoking in addition to usual NHS antenatal care.
Adherence
Participants allocated to receive the MiQuit intervention
will have an adherence check performed at the late preg-
nancy/postnatal follow-up stage, at 36 weeks gestation
(visit 3). At this stage participants will be asked basic
questions about their use of the texts sent.
If they wish, participants in both groups will be able to
access additional support to help them stop smoking;
they will all be asked about any use of support at each
contact.
Outcomes
There is no single primary outcome for this pilot trial,
which deals primarily with feasibility issues.
Feasibility outcomes
Feasibility outcomes include the following:
1. Recruitment rate of participants from pregnant
smokers attending trial centres.
2. For individual trial groups, proportions of
participants with validated smoking cessation data
collected between 4 weeks after randomisation until
late pregnancy (at approximately 36 weeks
gestation).
Cooper et al. Trials  (2015) 16:29 Page 4 of 163. For both trial groups combined, collection of
validated smoking cessation data, as above,
measured in late pregnancy (approximately 36 weeks
gestation).
Smoking outcomes
Smoking outcomes are described below:
1. Proportion of participants with self-reported,
continuous abstinence from smoking from 4 weeks
after randomisation until follow-up in late pregnancy
(approximately 36 weeks gestation), validated by
exhaled CO and/or saliva cotinine estimation; there
will be no ‘grace period’ [12]. Participants who
report smoking no more than five cigarettes in total
between the start of their quit attempt (within
4 weeks of randomisation) and late pregnancy will
be considered to have quit smoking [13].
(Note: Participants who cannot be contacted at
4 weeks after randomisation, but who, in late
pregnancy, report cessation as outlined above, will
be counted as positive for the late pregnancy
cessation outcome).
NB: We anticipate the above outcome being a
primary outcome for any definitive trial that follows
this study.
2. Proportion of participants with self-reported
abstinence from smoking from 4 weeks after
randomisation until late pregnancy (at approximately
36 weeks gestation).
3. Proportion of participants with self-reported and
validated 7 day point prevalence cessation measured
in late pregnancy (approximately 36 weeks gestation).
4. Proportion of participants with self-reported 7-day
point-prevalence cessation at 4 weeks after
randomisation.
5. Number of 24 hour quit attempts reported in late
pregnancy (approximately 36 weeks gestation).
Other outcomes
Other outcomes include the following:
1. Use of NHS cessation support.
2. Social cognitive variables such as health beliefs and
outcome expectancies.
3. Process variables such as number of contacts with
MiQuit for tailoring of content and increase or
decrease requests.
Assignment of interventions: allocation and blinding
After entering all baseline data onto a secure online
database, research midwives or central staff will ran-
domise participants via this database; however, these
staff will be unaware of the participant’s allocatedgroup. Randomisation will use a computer-generated
pseudo-random code with random permuted blocks
of randomly varying size, created by the Nottingham
Clinical Trials Unit and held on a secure server. The
randomisation will be stratified by site and gestation
(<16 weeks versus ≥16 weeks). The database will then
send an email to inform unblinded central adminis-
trators who are not involved in participant follow-up
of the allocation; they will then send participants an
information pack, which will provide further informa-
tion on participant allocation. Local hospital staff and
central staff involved in follow-up will remain blind to
treatment allocation as far as possible; however, as partici-
pants are not blinded it is possible that they may uninten-
tionally reveal their allocation during follow-up. In addition,
staff carrying out the final follow-up calls will need to ask
participants questions about the intervention and so will
become unblinded towards the end of this call. There
should be no other reasons why unblinding is needed.
Researchers carrying out the analyses will remain blind.
Further details are provided in the data collection sections.
Recruitment
Women will be recruited as they attend hospitals for
antenatal screening (ultrasound) appointments using
one or both of two different methods, depending on the
locally-available resources in participating Acute Trusts.
For both recruitment methods, all pregnant women at-
tending clinics will be asked to complete a brief ques-
tionnaire, which identifies smokers and asks those who
would like to receive self-help cessation support in the
context of a research study to provide contact details. A
PIS will be attached to the questionnaire. Questionnaires
will be distributed by a member of the patient’s usual
care team (for example, receptionist or midwife); infor-
mation about the trial will be displayed in relevant clin-
ical areas and adverts in clinic environments may also be
used to aid recruitment. The two methods of recruit-
ment are described as follows:
1. Via trial co-ordinating centre staff: A trust staff
member will oversee daily collation of questionnaires
and interested women’s contact details at each
recruiting site, sending these to a trial office by fax
or post. A member of the study team, who has been
appropriately trained, would then telephone
potentially-interested women and ensure that all
aspects pertaining to study participation are
verbally-addressed prior to obtaining consent.
2. Via staff in Acute Trust: This method of recruitment
will only be used in trial centres in which
Comprehensive Local Research Network (CLRN)
research midwives are available. Consent will, in the
main, be obtained in person by a CLRN research
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leave before consent can be obtained, a member of
the team may call and consent over the telephone as
for method one. A trust staff member or the RM
working within these recruiting sites will oversee
collation of questionnaires and the RM will follow
up face-to-face those respondents who are interested
in participating, usually while they are still in clinic.
The RM will offer trial enrolment to all eligible,
interested women ensuring that relevant aspects of
trial procedures are fully explained prior to obtaining
written informed consent. Those women who are
not able to wait will be asked (where possible) for a
convenient time to contact by telephone where the
process will be fully explained and consent provided
verbally.
This trial will, therefore, investigate the feasibility of
the two recruitment methods and will also provide an
estimate of CLRN resources that might be required for a
definitive study using the second recruitment method. A
variety of NHS Trusts will be used as recruitment sites
to encourage diversity of recruitment and increase gen-
eralisability. Reasons why potential participants are not
recruited will be collected and reported.Withdrawal of participants from intervention or
assessments
Participants may be withdrawn from the trial either at
their own request or at the discretion of the Investigator.
Participants who experience miscarriage or fetal death
will be advised to withdraw from the trial.
Individuals in the MiQuit arm may cancel text mes-
sages by sending a ‘STOP’ text message at any time dur-
ing the programme’s duration. However, unless they
specifically withdraw, they will remain in the trial as
participants.
Any participant who has already participated in the
study may not re-enter at a later date.Participant timeline and data collection
Pre-Screen
All potential participants will be identified via a brief
questionnaire, which will be attached to a participant in-
formation sheet.
Recruitment method one: For recruitment by this
method a member of the Co-ordinating centre study
team will complete and sign the consent form noting
that the consent was taken by telephone.
Recruitment method two: This will cover the details as
for method one, except that the participant can provide
either written or verbal informed consent; an RM work-
ing within the participating acute trust will explain allaspects of the study and will counter-sign the consent
form in both cases.
All participants will be asked to give written informed
consent for the collection of an exhaled breath and/or sal-
iva sample if they report a quit at the week 36 follow-up.
They will be made aware that the provision of samples will
only be required if a quit is reported at week 36 of their
pregnancy and that this may involve a visit to the partici-
pant’s home by the research midwife. If the participant is
not happy to be visited at home but is happy to provide a
saliva sample, postal sample kits are available. Carbon
monoxide levels in exhaled breath samples can only be
measured in person during a home visit.
Participants will also be given the option at the begin-
ning of the study to consent to be contacted by the
study team to discuss whether they would be interested
in being interviewed as part of an intervention process
evaluation. They will not be consenting to the interview
at the start of the study.
All participants will be provided with clear information
about how to withdraw their consent via Freepost post-
card (provided to all participants), text, email, or tele-
phone. In a similar trial in which we provided similar
methods to facilitate informed consent, fewer than 60
participants (from >2,500) withdrew consent after enrol-
ment [14].
Table 1 describes the participant assessments at each
stage. Figure 1 gives an overview of the study design and
measurement timepoints.
Visit 1 - baseline
After giving informed consent, participants will be asked
to complete a baseline questionnaire, which may be over
the telephone with the study team member (recruitment
method one) or over the telephone with a local RM or in
person by the RM (recruitment method two). This will
confirm contact details and ask about socio- demographic
data, smoking attitudes and behaviour (for MiQuit tailor-
ing), heaviness of smoking [15], gestational age, number of
births beyond 24 weeks, partner’s (significant other’s)
smoking status and health status (EQ-5D) [16].
The researcher will enter the participant details on the
electronic database and then randomise the participant.
This will ensure the researcher will remain blinded to the
participant allocation. The participants are randomised,
using the Nottingham Clinical Trials Unit's web-based ser-
vice, to intervention (MiQuit) or control. For participants
in either trial arm, a specific information sheet, which de-
scribes only details of procedures employed within that
arm, will be generated and sent to them by a non-blinded
member of the trial team who is not involved in follow-
up. Documentation will also include a leaflet giving some
information and advice on stopping smoking, details of a
contact point for participants who have questions about
Table 1 Participant assessments at each time point
Participants Assessments Pre-
screen
Visit 1:
Baseline
Randomisation Visit 2: 4 week
Follow-up
Visit 3: Late Pregnancy/
Postnatal Follow-up
Visit 4: Validation
of smoking status
Trial Unit (PS) X
Acute Unit (PS) X
Consenta,b X X
Visit Datesc X X X X
Demographics/Education X
Smoking Behaviour 1 X
Smoking Behaviour 2 X
Smoking Behaviour 3 X
Smoking Beliefs X X
Pregnancy X
Relationship Status X
Eligibility Criteria Check X
EQ-5D-3 Ld X X X
Allocation - MiQuit/Control X
Abstinence Check X
Stop Smoking Strategy/Quit
attempts
X
Attitude to Intervention
(MiQuit only)e
X
Assessment of Tobacco Exposuref X
aTelephone and written consent will be performed at Pre-screening.
bWritten consent for cotinine sample collection will be performed at V4 for those who provided telephone consent at pre-screening.
cTelephone/face to face visit will be performed at V1 (only) and face to face/postal visit will be performed at V4 (only). Visits 2 and 3 will be telephone, with
questionnaires sent to any who cannot be contacted.
dEQ-5D-3 L - European Quality of life Five Dimension, Three Levels questionnaire to be completed by the participant.
eA small number of those who are allocated to the MiQuit group and consent at baseline will be contacted for a qualitative telephone interview to provide
feedback on their experience of the study and intervention.
fMeasured with saliva cotinine and/or exhaled CO levels.
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verse their decision to take part (outlined in - removal of
participants from intervention or assessments). The PIS,
information sheets and consent form will be available in
English only, as understanding of English is required to re-
ceive the MiQuit intervention.
Follow-up contacts will use a blend of postal, tele-
phone, email/web and SMS text messaging reminders to
elicit maximal response rates. For those participants
reporting a quit, where possible, a home visit from their
local RM will be arranged.
Visit 2 - 4-week follow-up
At 4 weeks after randomisation, participants will be con-
tacted via telephone in order to assess smoking status,
numbers of quit attempts lasting more than 24 hours,
quality of life information (EQ-5D) and use of NHS and
non-NHS smoking cessation support in the period since
randomisation. This visit will, in general, be performed
via telephone by a member of the study team at the co-
ordinating centre, blind to treatment allocation; however,
should the study team be unable to contact by theparticipant by telephone, other methods will be used in
an attempt to elicit the best response. These include;
posting a short questionnaire with explanatory letter and
pre-paid return envelope, or sending a link, which allows
web-based completion or by text.
It is possible that if members of the co-ordinating
centre study team speak to participants at the 4-week
follow-up, they may become un-blinded for the late
pregnancy follow-up (visit 3). However, the value of ex-
ploring the feasibility of different follow-up approaches
for this pilot trial outweighs the small risk of bias pre-
sented by this scenario.
Visit 3 - late pregnancy/postnatal follow-up
At 36 weeks gestation: Participants will be asked to
complete a questionnaire (data to be collected up to
10 weeks after estimated delivery date will be acceptable
for use). This will include quality of life information (EQ-
5D) and measures of smoking behaviour, attitudinal/behav-
ioural information, use of NHS smoking cessation support
and participants’ ratings of the intervention (MiQuit arm
only). As for the 4-week visit, this visit will be performed
Figure 1 Participant flowchart: study design and the timeframe for follow-up assessments.
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co-ordinating centre, blind to treatment allocation. As for
the 4-week visit, previously-described alternative methods
will be employed to elicit the best response rate.
It is recognised that asking about the intervention at
follow-up will result in the researcher who conducts the
late pregnancy follow-up becoming un-blinded. To en-
sure that this has minimal impact on follow-up data ob-
tained, the participants will be asked items about the
intervention at the end of the interview/questionnaire
starting with the question ‘Did you receive any stop
smoking text messages from the study team?’
Visit 4 - validation of smoking status
During this assessment, whether in person or by post,
participants will be asked to report their smoking status
and recent use of nicotine replacement therapies.
Participants self-reporting abstinence in late pregnancy
will have their smoking status validated by exhaled car-
bon monoxide (CO) readings and/or salivary cotinine
samples. The validation of smoking cessation would be
initiated as soon as possible after notification of abstin-
ence at visit 3.
Exhaled CO will be measured using a validated hand
held CO monitor and can only be taken when a re-
searcher is able to visit the participant in their home.
Saliva samples for cotinine (a metabolite of nicotine)
analysis could be collected at the same visit. Ideally both
forms of assessment would be used, but either CO or
cotinine assessment would be sufficient on their own if
difficulties in getting a valid sample are experienced with
either method. Where it is not possible to visit a partici-
pant in their home, a salivary sample pack will be sent
by post and participants will be invited to return a sam-
ple in a pre-paid postal packet. Written consent agreeing
to provide the samples for validation will be obtained
from any participants who did not give this consent at
baseline (that is, those who were recruited via tele-
phone). This consent will be obtained either during the
home visit or by sending a consent form for the partici-
pant to complete and return with a postal saliva sample.
Cut-off points for biochemical verification will be deter-
mined according to the latest evidence, but defined ab-
stinence is likely to be in the region of <9 ppm for CO
readings and <10 ng/ml for salivary cotinine [17].
Duration of the trial
It is anticipated that the total duration of the study will
be 20 months. This will include 12 months of recruit-
ment and 8 months of follow-up.
Late pregnancy outcome ascertainment is intended to
be at 36 weeks gestation, or at latest, within two weeks
of birth. However, if outcome data become available
after this point, we will permit it to be used in analysesprovided the timing of data collection is no later than
10 weeks after the estimated due date.
Qualitative interviews undertaken as part of a process
evaluation will be carried out shortly after the late preg-
nancy follow-up and are not planned to be carried out
any later than 10 weeks after the estimated delivery date.
End of the trial
The end of the trial will be when the late pregnancy out-
come has been ascertained for the final participant or it
is too long after this participant’s estimated delivery date
(EDD) for such information, if collected, to be used.
Participant stipends and payments
All participants will receive compensation for their time
to the value of £5 for each study visit in the form of a
national high street shopping voucher. Those partici-
pants who are asked to provide a saliva sample will be
sent a £5 voucher with the sample request pack and a
second £5 voucher on receipt of a saliva sample. Those
participants who participate in a longer in-depth qualita-
tive interview to gain information on their experience of
the intervention (MiQuit arm only) will receive £20 in
vouchers as compensation for their time.
Qualitative interviews for process evaluation
A small number of semi-structured telephone interviews
will be carried out with a selection of participants from
the MiQuit arm in order to address secondary objective
4. This process evaluation will provide important data
on participant’s experience of receiving support from
MiQuit within the context of their everyday lives and
participation in a trial. Semi-structured interviews will
enable the researcher to have some control over the data
collected to compliment the trial evaluation but at the
same time be interactive and allow the participant con-
trol also. The findings will greatly assist the design of a
definitive trial and optimisation of the intervention.
Participants will be purposively selected according to
smoking status and cessation behaviour and use of the
MiQuit system, including those who decide to discon-
tinue use of MiQuit. Only participants who have already
consented at baseline to be contacted to discuss partici-
pation in an interview will be contacted and will receive
additional information before the call on what to expect.
After completing the late pregnancy follow-up, partici-
pants in the MiQuit arm, who indicated at baseline that
they were happy to be contacted about participation in
an interview, will be sent a specific information sheet
and blank consent form. A researcher will call a number
of participants (not all) and establish if the participant is
still interested in going ahead with the interview. If they
are happy to continue, the researcher will request verbal
consent for the interview and proceed with the interview.
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the interview at that time, a specific date will be set for the
interview to take place. In every case, verbal consent will
be recorded by the researcher before the interview goes
ahead, and a copy of the consent form will be sent to the
participant. The participant will be made aware that the
interview will be audio-recorded and that they can with-
draw from the interview at any time and that this would
not affect their subsequent care or rights. Participants will
be recruited until the researchers feel that data saturation
has occurred (that is, the point where few novel insights
are generated from the most recent interviews). Given the
focused nature of the interviews, it is anticipated that this
would be reached after interviewing 10 to 15 participants.
The interview schedule will include questions on the
participants’ general experience of smoking and quitting
during pregnancy, their experience of using and inter-
acting with MiQuit, their feelings towards whether and
how MiQuit might have helped them engage or main-
tain a quit attempt, and their thoughts on how it could
be improved.
The interviews will be undertaken by experienced
personnel and last up to 60 minutes. The interviews will
be analysed using framework analysis, assisted by the
qualitative analysis software NVivo. This will include look-
ing at two main characteristics of the participants: that is,
smoking status and use of system including those who dis-
continue (text STOP) and how these relate to several as-
pects of the experience of receiving the intervention
including factors that may affect interaction with MiQuit,
feelings towards message content and system features and
suggestions for improvements for future use.
A number of semi-structured telephone or face to face
interviews will also be carried out with a selection of
recruiting site research staff involved in the study in
order to address secondary objective 5. This will provide
important data on the staff experience of running and
recruiting into the MiQuit study. As for the participant
interviews, the semi-structured interviews will enable
the team to have some control over the data collected to
complement the trial evaluation but also be interactive
to allow the local site research staff to have some control
too. The findings will greatly assist the practical design
of a definitive trial.
A number of staff from recruiting centres will be se-
lected for interview, to allow a variety of opinions and
comments to be collected.
The objectives for these interviews are as follows:
1. To develop a taxonomy for describing MiQuit trial
recruitment processes.
2. To describe research midwives’ perceptions of the
key facilitators for and barriers against
recruitment.3. To relate key facilitators and barriers to recruitment
processes and so further understanding of how, in a
definitive trial, recruitment could be maximised.
4. To describe from the perspective of research
midwives, those factors, which are perceived to
influence acute trusts’ decisions to act as a trial
centres (NB: after analysis, we will be in a position to
hypothesise about how best to encourage trusts to
sign up to being trial centres in a definitive study).
Issues to be covered in staff interviews will include the
following:
1. The particular process they used in their site to
identify, engage and enrol participants, including the
consent process;
2. their views on the local trial processes, including
why particular processes were used, what worked
well or was challenging, what the study team could
have done to make this easier, particularly focussing
on issues that it is possible to influence;
3. how decisions are made about Trust involvement in
a particular trial and what influenced them to take
part, whether they would consider being involved in
a similar study again, insights into best way to
achieve meaningful collaboration; and
4. their views on the intervention.
The interviews will be audiotaped and analysed using
thematic qualitative analysis.
Statistical methods
Sample size and justification
1. Estimation of key trial parameters
The primary objective of this pilot trial is to demon-
strate the feasibility of running a definitive, multi-centre
trial of the MiQuit interevention within an NHS context;
with 400 participants, the following key parameters will
be estimable within the precision indicated (figures pre-
sented are margin of error = half width of 95% confi-
dence interval):
a. the recruitment rate of participants from within
smokers attending trial centres/hospital to within
+/− 1%,
b. for individual trial groups, proportion of participants
with validated smoking cessation between 4 weeks
after randomisation until late pregnancy to within +/−
4%, and
c. for both trial groups, the combined proportion of
participants who quit in late pregnancy (cessation as
defined above) to within +/− 3%, assuming that the
Cooper et al. Trials  (2015) 16:29 Page 10 of 16actual proportion of participants quitting is around
10%.
2. Estimate for short-term efficacy
A secondary objective of this pilot trial is to estimate the
effectiveness of the MiQuit intervention for promoting
smoking cessation. Providing evidence to support the no-
tion that this intervention is likely to be effective would in-
crease the research team’s future chances of obtaining
funding to conduct a definitive trial. We will investigate ef-
ficacy of MiQuit at 4 weeks after randomisation by com-
paring self-reported, 7-day, point-prevalence, cessation
rates between trial groups. It should be noted that this is a
surrogate end point for that which we plan to use in any
definitive trial; a potential strength of using this is that
event rates (that is, proportion of participants achieving
cessation) are likely to be higher at this time point, which
is closer to randomisation than the late pregnancy-
assessment point, and this could provide greater power to
detect between group differences. A potential disadvantage
is that the relationship between this surrogate endpoint
and cessation in late pregnancy (approx 36 weeks) is not
known; consequently, findings using data obtained at this
time point should not be used in isolation to assess
whether or not a definitive trial should be conducted.
Consequently, using 95% and 80% confidence intervals
(CIs), Tables 2 and 3 illustrate for this trial with 400 partic-
ipants, the precision for detecting different ORs represent-
ing differences between groups over a range of control
group event (that is, quit) rates. The choices of parameters
for the tables are explained below.
Control group event (quit) rates: There are few data
with which we can estimate control group event (that is,
proportion of participants achieving cessation) rates at
1 month after randomisation, but accurate estimates are
important to inform meaningful sample size estimates.
One recent trial (MiQuit feasibility trial), tested a very
similar version of this trial’s intervention, but in this
study 7-day point-prevalence abstinence was measured
in similar manner as we propose at 12 weeks after ran-
domisation, rather than at 1 month after; in this trial,
the control group quit rate was 19.6% [11]. Two recent
UK trials have enrolled pregnant smokers, albeit withTable 2 Estimates for treatment effect: precision estimates pr
95% CI
Odds ratio
10% control event rate
N = 200 in each group
1.3 0.70 to 2.42
1.5 0.82 to 2.76
1.8 1.0 to 3.26different characteristics, and have measured cessation out-
comes at 1 month after randomisation. A trial of nicotine
patches found a 14% control group rate of self-reported,
prolonged cessation between randomisation and 1 month
[18], and control group women recruited to an exercise
intervention RCT had a 13.7% validated abstinence rate,
again for reported, prolonged abstinence during the same
period (unpublished findings) [19]. Overall, therefore, as-
suming that control group quit rates will fall within in a
10 to 20% range seems reasonable.
3. Estimates for treatment effect
MiQuit is a self-help intervention and a systematic re-
view of self-help interventions used for smoking cessa-
tion in pregnancy found a pooled estimate for the
effectiveness of these, which corresponds to an Odds Ra-
tio (OR) and (95% CI) in favour of using such interven-
tions of 1.83 (1.23 to 2.73) [7]. Using data obtained at
3 months after randomisation, the MiQuit feasibility trial
found an OR in favour of using MiQuit of 1.68 (0.66 to
4.31) [11]. Consequently, using a range of OR from 1.3
to 1.8 is appropriate.
Estimating cessation in late pregnancy: For modelling
analyses, we will use a trial-derived estimate for the
treatment effect of the intervention derived from
between-group differences in validated, longer term quit
rates, measured in late pregnancy (that is, at approxi-
mately 36 weeks gestation). Again deriving this estimate
is a secondary objective of the trial. Tables 4 and 5 use
95% and 80% confidence intervals (CIs), to illustrate for
this trial with 400 participants, the precision for detect-
ing different ORs representing differences between
groups over a range of control group event (that is, pro-
portion of participants achieving cessation) rates. The
proportion of participants in the control group who quit
is based on 5% and 10%, as this reflects findings in the
three trials described above [11,18,19].Data analysis
Members of the research team, led by the study statisti-
cian, will undertake the analyses. A full statistical analysis
plan will be finalised and agreed by the Trial Steering
Committee prior to data analysis. Initially, participants inesented as 95% confidence intervals
15% control event rate
N = 200 in each group
20% control event rate
N = 200 in each group
0.77 to 2.20 0.81 to 2.09
0.90 to 2.51 0.94 to 2.39
1.09 to 2.98 1.14 to 2.85
Table 3 Estimates for treatment effect: precision estimates presented as 80% confidence intervals
80% CI
Odds ratio
10% control event rate
N = 200 in each group
15% control event rate
N = 200 in each group
20% control event rate
N = 200 in each group
1.3 0.87 to 1.95 0.92 to 1.83 0.95 to 1.77
1.5 1.01 to 2.23 1.07 to 2.10 1.11 to 2.03
1.8 1.22 to 2.65 1.29 to 2.51 1.33 to 2.43
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with respect to the following:
1. Centre
2. Age at randomisation
3. Ethnic group (white, other)
4. Gestation at randomisation (<16 weeks, 16+ weeks)
5. Heaviness of smoking
6. Number of births beyond 24 weeks,
7. Previous history of prenatal smoking
8. Partner/significant other’s smoking status
9. Participant’s health status (EQ5D)
10. Participant’s motivation to quit
Analyses will primarily address the feasibility objec-
tives of the study. We will determine the recruitment
rate, with 95% confidence intervals, of participants who
take part in the study from pregnant smokers attending
trial centre. For each trial treatment group, we will esti-
mate the proportions of participants, with 95% confi-
dence intervals, achieving validated smoking cessation
between 4 weeks after randomisation until late preg-
nancy (at approximately 36 weeks gestation). We will
also estimate the proportion of participants, with 95%
confidence intervals, who achieve validated smoking ces-
sation in late pregnancy (approximately at 36 weeks ges-
tation) for both trial groups combined.
We will perform chi-squared tests to assess the associ-
ation for the proportion of participants who achieve 4-
week and late-pregnancy smoking outcomes between
the trial treatment groups. Logistic regression models
will then be used to compare the outcomes between the
two trial groups with adjustment for factors used to
stratify the randomisation (centre and gestation at ran-
domisation; <16 weeks versus ≥16 weeks) through in-
cluding these as fixed covariates in the model. These
analyses will be pragmatic and based on intention-to-
treat. Additionally, we will create the following graphs toTable 4 Estimating cessation in late pregnancy: precision esti
95% CI
Odds ratio
5% control event rate
N = 200 in each group
1.3 0.56 to 3.05
1.5 0.66 to 3.44
1.8 0.81 to 4.02look at the pattern of the outcome response across
centres:
1. Average outcome in the intervention group versus
the average outcome in the control group per
centre.
2. Average difference in outcome between the
intervention and control groups per centre versus
centre.
Further multiple logistic regression analyses will be
conducted to assess the strength of association between
baseline covariates and 4-week and late-pregnancy
smoking outcomes, which will include the following:
1. Heaviness of smoking.
2. Partner/significant other’s smoking status.
3. Education as a measure of SES.
These variables have been chosen as potentially requir-
ing adjustment because, in previous studies, they have
been shown to be associated with smoking cessation in
pregnancy [20,21].
Other smoking outcomes will be analysed using similar
methods: 95% confidence intervals will be presented along
with exact two-sided P values. Descriptive analyses will be
performed to assess the effect of the intervention on the
use of NHS cessation support, use of interactive features
of the intervention and social cognitive variables.
We also plan to explore the mechanism of effect for
the MiQuit intervention that is, how the intervention
might change smoking behaviour. For this, we will
undertake mediation analyses to explore whether poten-
tial changes in social cognitive determinants of smoking
cessation explain changes in quitting behaviour. This will
be a secondary analysis and, therefore, covered in a sep-
arate paper rather than in the main trial outcomes
paper.mates presented as 95% confidence intervals
8% control event rate
N = 200 in each group
10% control event rate
N = 200 in each group
0.65 to 2.58 0.70 to 2.42
0.77 to 2.93 0.82 to 2.76
0.94 to 3.46 1.0 to 3.26
Table 5 Estimating cessation in late pregnancy: precision estimates presented as 80% confidence intervals
80% CI
Odds ratio
5% control event rate
N = 200 in each group
8% control event rate
N = 200 in each group
10% control event rate
N = 200 in each group
1.3 0.75 to 2.27 0.83 to 2.04 0.87 to 1.95
1.5 0.87 to 2.58 0.97 to 2.33 1.01 to 2.23
1.8 1.06 to 3.05 1.18 to 2.76 1.22 to 2.65
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incremental cost-effectiveness of MiQuit using costs (ac-
tual and estimated) of delivering the intervention and es-
timates for its effectiveness derived from the trial.
Models developed in previous studies will be used to
project the likely cessation rates into longer term esti-
mates of life years gained.
Assessment of efficacy
The smoking outcome measure used to estimate efficacy
will be self-reported, prolonged abstinence from smok-
ing from 4 weeks after randomisation until late preg-
nancy, validated by exhaled CO and/or saliva cotinine
estimation. Smoking up to five cigarettes during the ab-
stinence period will be permitted and consistent with a
positive outcome.
Assessment of safety
As this evaluation concerns a behavioural intervention
we are not assessing any safety variables or collecting
any adverse events.
Procedures for missing, unused and spurious data
Our primary analyses will use an intention-to-treat ap-
proach, analysing all participants’ outcome data within
the intervention group to which they were randomised,
assuming, as is consistent with the Russell Standard, that
participants with missing smoking status data are smok-
ing [13]. Participants are advised to withdraw from the
study if they have a miscarriage or still birth or where
the infant has died following birth; however, if they do
not and this is established at follow-up they may decline
to provide information. These women will be included
in the analyses and assumed to be smoking.
For the descriptive analyses, where there are missing
baseline socio-demographic data, a separate category will
be created and reported to represent the missing data.
For statistical analyses involving socio-demographic vari-
ables with missing data, if the proportion of missing data
is <5% and roughly similar in both intervention groups,
then we will explore the robustness of using a complete-
case analysis and an analysis including allowing for the
missing data through analysing missing data as a separate
category. If >5% of socio-demographic data are missing,
then we will consider using imputation methods, such asmultiple imputations. The impact of the imputations
methods will be assessed fully in sensitivity analyses.
Definition of populations analysed
For the efficacy and cost-effectiveness estimate assess-
ments, all randomised participants will be used in the
analyses using intention-to-treat population as defined
below. All participants in the intention-to-treat popula-
tion will be used for establishing use of NHS smoking
cessation support and for the mechanism of effect
analysis.
Intention-to-treat population
The intention-to-treat (ITT) population is defined for
this trial as all pregnant smokers who were randomised
into the trial. Participants will be analysed based on the
intervention group to which they were randomised. For
participants with missing smoking-related outcomes, we
will use the Russell Standard, where these participants
will be assumed to be smoking [13].
Sensitivity analyses
Two populations will be used for the sensitivity analyses
on the 4-week and late-pregnancy smoking outcome
measures:
1. All pregnant smokers who were randomised into the
trial, and who have outcome data available for
analysis (complete case analysis). Participants will be
analysed based on the intervention group to which
they were randomised.
2. All pregnant smokers who were randomised into the
trial, and who, in the intervention group, self-
reported at follow up that they received the inter-
vention leaflet and text messages (per protocol
analysis).
Health economics
Per-participant costs of providing the MiQuit service will
be calculated. and EQ-5D data will be used with this to es-
timate the incremental cost-effectiveness of offering the
MiQuit intervention. Given that this is a pilot study rather
than a definitive trial, it is acknowledged that the estimate
for incremental cost-effectiveness will have limited accur-
acy and so a range of different potential values will be used
to model the potential lifetime cost effectiveness of
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ling will use i) estimates for uptake of NHS services by
smokers and non-smokers after pregnancy, which have
been derived from a similar recent trial that employed
post-partum follow up [18], and ii) a model, which values
smoking cessation in pregnancy in economic terms and is
currently being developed by a PhD student.Data management
Data will be entered electronically on a trial specific
database. Only research midwives and the research study
team will have database access, which permits them to
make new entries and also to access relevant personal
data collected from participants at their sites (for ex-
ample, contact details).
To enable anonymisation, each participant will be
assigned a unique trial identity code number, allocated
at randomisation, for use on all trial documents and the
electronic database.
The database will be maintained on a server located
within the Nottingham Clinical Trials Unit, University of
Nottingham (Chief Investigator’s institution). The data-
base has a regular back-up routine, and will be password
protected.
Anonymised data, which have been sent to MiQuit
and which have been used to individualise SMS text
messages, will be held on a secure server within the In-
stitute of Public Health at the University of Cambridge.
Only authorised trial staff shall have access to trial docu-
mentation other than for the regulatory requirements.
All trial staff and investigators will endeavour to pro-
tect the rights of the trial’s participants to privacy and
informed consent and will adhere to the Data Protection
Act, 1998.
Electronic data will be backed up every 24 hours to both
local and remote media in encrypted format. Electronic
audio files of the interviews will be stored in an encrypted
format. Transcribed interviews will be anonymised.
Monitoring of trial data shall include confirmation of
informed consent; source data verification; data storage
and data transfer procedures; local quality control
checks and procedures, back-up and disaster recovery of
any local databases and validation of data manipulation.
The Trial Manager, or where required, a nominated des-
ignee of the Sponsor, shall carry out monitoring of trial
data as an on-going activity.
All records and documents regarding the conduct of
the study will be retained for at least 7 years or for lon-
ger if required. The trial master file and trial documents
held by the Chief Investigator on behalf of the sponsor
will be archived at secure archive facilities at the Univer-
sity of Nottingham. This archive shall include all trial
databases and associated meta-data encryption codes.Transport, storage and analysis of saliva samples
The use of oral fluid samples (saliva) is a non-invasive
way of measuring cotinine, a nicotine metabolite [22].
Saliva samples will be collected at visit 4 (around
36 weeks gestation) to verify smoking status by a re-
searcher or by post if a visit is not possible. Saliva sam-
ples will be obtained using clean salivettes; it will involve
the participant placing a sterile swab under the tongue,
for up to 5 minutes until it is moist and then placing the
swab into a sterile vessel. All samples will be stored in a
linked anonymised format in a secure freezer storage
unit (−20°C) within Nottingham Health Science Biobank
(NHSB) according to their approved protocols. Where
researchers obtain samples by visiting participants who
live at a distance that would make it impractical to de-
liver these to Nottingham in person, these samples will
be posted by the study team in suitable packaging, and
when received, the study team will transfer them to
NHSB. Samples are stable at ambient temperatures for
several days. For postal samples, the participant will be
asked to state the date they provided the sample on the
label. Participants will be advised to return the sample
(using the protective pre-paid and addressed packaging)
on the day they provide the sample. Again these will be
transferred to the NHSB by a member of the study team.
Nottingham Health Science Biobank has been given full
approval by the HTA to be a full licence holder, meeting
all legislation requirements.
Once all samples have been collected for the study,
NHSB will arrange transportation of samples by courier
to ABS Laboratories Ltd, Hertfordshire for analysis in a
single batch shipment. The shipment will contain a
complete inventory of all samples, along with the name
of the person responsible for sending the samples. The
master database to link all samples will be held by the
Nottingham study team in a password encrypted file.
The laboratory will quantify salivary cotinine levels using
a quantitative enzyme immunoassay technique (EIA).
Once the analysis has been completed the saliva samples
will be destroyed in accordance with the Human Tissue
Act 2004, this will only occur once the study team have
received the results and have analysed the data to ensure
that all samples remain in a normal range and do not re-
quire retesting.
Dissemination
Results will be written up for publication in peer
reviewed journals and disseminated at local, national,
and international meetings where appropriate. A lay
summary will be produced and distributed to those par-
ticipants who have indicated they would like to receive a
copy and other interested parties.
Participants will not be identified in any publications
or presentations resulting from this study.
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A Public and Patient Involvement representative has
contributed to this protocol, to trial documents and to
the development of the intervention. In addition, several
individuals who took part in a pilot trial of MiQuit have
been consulted and have provided guidance on the re-
finement and delivery of MiQuit.
Indemnity
Insurance and indemnity for trial participants and trial
staff is covered within the NHS Indemnity Arrange-
ments for clinical negligence claims in the NHS, issued
under cover of HSG (96)48.
The University of Nottingham as research Sponsor in-
demnifies its staff, research participants and research
protocols with both public liability insurance and clinical
trials insurance. These policies include provision for in-
demnity in the event of a successful litigious claim for
proven non-negligent harm.
Trial management
The Chief Investigator has overall responsibility for the
study and will oversee all study management. The Trial
Management Group (TMG) will be responsible for the
day to day running of the trial. The TMG will be sup-
ported by and report to an independent Trial Steering
Committee. Trial co-ordination will be managed cen-
trally by the study team based in Nottingham led by a
trial manager and guided by the TMG. The Cambridge
research team will manage a server hosting the MiQuit
intervention; however, the Chief Investigator (Nottingham)
will be custodian of all study data.
Ethics approval
Ethical approval for this study was granted by Notting-
ham 1 Research Ethics Committee (NRES reference 13/
EM/0427).
Sponsor
The trial is sponsored by the University of Nottingham.
Discussion
Once completed, this pilot trial will provide the neces-
sary data to plan for larger definitive study to investigate
whether or not self-help cessation support [7] provided
in an interactive text message format can help pregnant
women to achieve cessation. This pilot trial provides in-
formation, which complements that from our earlier
feasibility trial [11] and has been necessary for a number
of reasons.
First, the primary outcome for the earlier study was
self-reported, 7-day, point-prevalence, smoking cessation
[12] measured at 12 weeks after trial entry [11]. Whilst
any period of smoking cessation is likely to be beneficialfor pregnant women and their infants, maximal health
gain for infants is likely to occur if mothers maintain ab-
stinence throughout pregnancy. Additionally, it is pos-
sible that women who remain smoke free for the whole
of pregnancy will be better able to avoid relapse back to
smoking after childbirth and, for both reasons, a defini-
tive study should aim to detect any impact on women’s
smoking throughout the whole of pregnancy. Most
smoking cessation trials encourage participants to set a
quit date and cessation outcomes are measured pro-
spectively from this point; however, MiQuit is a ‘cessa-
tion-induction’ intervention, which encourages, but does
not require users to set a definite quit date. Finding ap-
propriate time points in pregnancy from which continu-
ous cessation can be measured, monitored and validated,
after participants have been exposed to MiQuit, is an
important issue that the pilot trial is attempting to re-
solve. Achieving high ascertainment rates for piloted
methods of measuring continuous cessation will mean
that our piloted outcome could be used to measure and
validate smoking cessation throughout the whole of
pregnancy in any future definitive RCT.
Second, the treatment effects attributable to smoking
cessation interventions are generally inversely propor-
tional to their intensity [23] and MiQuit is a low-
intensity intervention. For a definitive study to have
sufficient power to show whether or not MiQuit has
efficacy for smoking cessation in pregnancy, such a study
could need a sample size of over 3,000 participants (esti-
mated using data from previous MiQuit trial [11]).
Clearly, to plan a definitive study that combines a suffi-
ciently high chance of providing a definitive answer with
efficient use of resources, the best possible information
is needed. This pilot trial will provide the first estimate
for the treatment effect that MiQuit might have for in-
fluencing continuous smoking cessation between earlier
and later (approximately 36 weeks) pregnancy; although
the pilot is not powered to provide such an estimate
with high precision, it will nevertheless, be a very valu-
able parameter. Additionally, knowing the combined
treatment groups’ cessation rates at 36 weeks will also be
useful to inform definitive-trial sample size calculations.
Third, recruitment rates from this study will be vital
for assessing the feasibility of delivering a large definitive
RCT investigating smoking cessation in pregnancy and
using English National Health Service (NHS) research
structures. Since 2006, the English NHS has developed
and revised research networks, funded from the health
service budget and orientated towards delivering clinical
research; there is a particular focus on RCTs that influ-
ence clinical practice [24]. Networks provide staff work-
ing across the NHS whose remit is to recruit to research
studies and researchers who successfully access network
staff support can efficiently deliver multi-centre RCTs.
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subsequently finding the most efficient ways of combin-
ing their efforts with those of a university-based research
team can be challenging and, significantly the two most
recent English pregnancy smoking cessation trials
[18,19] were completed with relatively little research net-
work input. To date, overall pilot trial recruitment has
been strong and it appears that study methods could,
feasibly be used to recruit to a larger definitive study.
However, across the 16 trial centres from which this
pilot recruits, there has been marked variation in re-
cruitment rates. Consequently, lessons learned from our
planned pilot trial process evaluation should help us to
better understand the reasons for different recruitment
rates in different centres and, potentially to enhance the
research network staff experience of recruiting to the
trial for any future study.
Given the nature of this pilot trial, discussion has princi-
pally focussed on methodological issues. However, if after
this study, a definitive RCT is conducted and MiQuit is
found to be effective for smoking cessation in pregnancy,
this very cheap and likely (in that circumstance) highly
cost-effective intervention could easily be made very
widely available in many different ways to support smok-
ing cessation in pregnancy.
Trial status
Recruitment began in February 2014, with the first par-
ticipant randomised on 18 February 2014. At the time of
the manuscript submission, the trial was still recruiting
with 385 recruited by 27 August 2014. This article is
based on protocol version 2.0, 14 May 2014.
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